<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">NGUYEN, MINH DUNG</style></author><author><style face="normal" font="default" size="100%">GOROBETS, OLENA</style></author><author><style face="normal" font="default" size="100%">DJOUA, YANNICK JOEL</style></author><author><style face="normal" font="default" size="100%">ROSE-DITE-MODESTINE, JOHAN</style></author><author><style face="normal" font="default" size="100%">VINH-HUNG, VINCENT</style></author><author><style face="normal" font="default" size="100%">VERSCHRAEGEN, CLAIRE</style></author><author><style face="normal" font="default" size="100%">NGUYEN, NAM P.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2535-2538</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.17625</style></doi><volume><style face="normal" font="default" size="100%">45</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Enzalutamide is a highly effective anti-androgen for the treatment of prostate cancer. Therapy can incur unbearable fatigue in elderly patients, which might require a reduced dosage. However, the value of reduced-dose treatment to improve the long-term tolerability and to decrease the risk of toxicity remains unknown.Case Report: We present the six-year clinical course of a patient treated upfront with low-dose enzalutamide (25% of the standard dose). Despite initial disease control and tolerance, the patient developed progressive frailty and signs of severe androgen deprivation near end-of-life.Conclusion: This case illustrates that while low-dose enzalutamide can provide durable disease control in elderly patients with metastatic castration-resistant prostate cancer, it does not fully prevent the late-onset toxicities associated with androgen deprivation. Personalized treatment strategies – including dose adjustment over time and consideration of intermittent therapy – may help to balance efficacy with quality of life.</style></abstract></record></records></xml>